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ABSTRACT 
Objective: The aim of present work was to the development of control release 0.1% tazarotene microsponge and incorporated into a HPMC K-100M 
gel. 
Methods: Drug compatibility with polymer was evaluated by FT-IR spectrum. Tazarotene microsponge was prepared by quasi-emulsion solvent 
diffusion method. On the basis of preliminary results, 32 full factorial design was employed to study the effect of Eudragit RS-100 conc. (X1) and PVA 
conc. (X2) on as particle size (Y1), % drug entrapment (Y2) and time required to 80% drug release (Y3). Multiple linear regression analysis, ANOVA 
and graphical representation of the influence factor by 3D plots were performed by using Sigma plot 11.0. In this study, the following constraints 
were arbitrarily used for the selection of an optimized batch: particle size<200 µm, drug entrapment>70 %, and time required to 80% drug 
release>360 min. The optimized formulation was subjected to SEM study. Tazarotene microsponge incorporates in 3% HPMC K-100M gel evaluated 
for viscosity, pH, drug content, spreadability, In vitro diffusion study, release kinetic study and photostability study. 
Results: The FT-IR result showed that there was no chemical interaction and SEM photograph indicates that microsponges are spherical and pores. 
From the results of multiple regression analysis, it was found that all factors had a statistically significant influence on all dependent variables.  
Conclusion: The optimized formulation of gel release kinetics having good linearity (R2= 0.987) of zero-order kinetic and it was found to be stable 
in the stability evaluation. 
Keywords: Tazarotene, Microsponge, Controlled release, Topical gel, 32full factorial designs 




Conventional topical drug delivery systems require high 
concentrations of drug for effective therapy because of their low 
efficiency as delivery systems. Thus, the need exists for topical 
delivery systems to maximize the period of time active ingredient is 
present, either on skin surface or in epidermis. Microsponges are 
porous and polymeric microspheres that are mostly used for 
prolonged topical administration. Microsponges are designed to 
minimum dose, enhance stability, reduce side effects and modify 
drug release profiles [1, 2]. 
Tazarotene is a retinoid prodrug which is converted to its active 
form, the cognate carboxylic acid of tazarotene by rapid de-
esterification in animals and man. Tazarotene, 0.1% was US Food 
and Drug Administration (USFDA) approved in 2012 for the 
treatment of acne vulgaris. Tazarotene systematic bioavailability is 
very low (approximately 1%) because of minimum systemic 
absorption and rapid metabolism. It causes severe side effect like 
skin irritation, sensitization, and phototoxicity. Tazarotene 
microsponge will minimize the side effect and allow control release 
delivery. The limited penetration of tazarotene from microsponge 
retards the rapid metabolism and its helps to prevent the drug build 
up in the body’s lipophilic tissues [3-5]. 
So, the present work was carried out to develop tazarotene 
microsponge for topical drug delivery in the form of hydrophilic gel 
formulation which will prevent side effect of the drug and reduce its 
metabolites in skin. 
MATERIALS AND METHODS 
Materials and reagents 
Tazarotene was received as a generous gift from Sun Pharma, 
Baroda, India. Eudragit RS-100 was obtained from Evonic Degusa, 
Mumbai, India. Eudragit RL-100, HPMC K-100M, Ethyl Cellulose and 
Polyvinyl alcohol were purchased from Loba Chemicals, Mumbai. 
Dichloromethane and methanol were obtained from Ren Chem labs, 
New Delhi, India. All other materials and chemicals used were of 
either pharmaceutical or analytical grade.  
Drug excipients compatibility study 
Drug-Excipients interaction plays a vital role in achieving the 
stability of the drug in dosage form. Fourier transform infrared 
spectroscopy (FT-IR) was used to study the physical and chemical 
interactions between drug and excipients. FT-IR spectra of 
Tazarotene, Eudragit RS-100 and Mixture (Tazarotene and Eudragit 
RS-100) were recorded using KBr mixing method on FT-IR 
instrument. (FTIR-1700, Shimadzu, Kyoto, Japan) [6, 7]. 
Preliminary screening of formulation parameters and 
development of tazarotene microsponge 
Preliminary trial of tazarotene microsponge was done by selecting 
parameters such as polymer conc., Speed and PVA concentration on 
% drug entrapment, % yield, drug content and mean particle size. 
Tazarotene microsponge was prepared by a quasi-emulsion solvent 
diffusion method. In this, method internal phase was prepared by 
dissolving required amount of tazarotene and polymer (Eudragit RS-
100, Eudragit RL-100, Ethyl cellulose) in 100 ml dichloromethane 
and 8 ml methanol at 60 °C. External phase was prepared by 
dissolving 0.5% and 1% polyvinyl alcohol (PVA) in distilled water as 
shown in table 1. Internal phase was gradually added into external 
phase at 500 rpm, 1000 rpm and 1500 rpm with help of Magnetic 
Stirrer (REMI Equipment, India). After emulsification, the mixture 
was continuously stirred for 3 h. Then, the mixture was filtered and 
separates the microsponges. This prepared microsponge was 
washed with distilled water and dried by hot air oven at 40 °C for 24 
h. All the batches were stored properly and evaluation was carried 
out [8, 9]. 
Evaluation parameters of tazarotene microsponge 
Particle size analysis: Particle size analysis of tazarotene 
microsponge was analyzed by optical microscopy method, using 
calibrated eye piece and stage micrometer slide.  
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% Yield: The % yield of the tazarotene loaded microsponge can be 
determined by the following equation:  
Production yield =
Practical Mass of Microsponges 
Theoretical Mass (Polymer + Drug )
× 100  
% Drug entrapment: The % Drug entrapment of the microsponges 
can be calculated according to the following equation:  
% Drug entrapment=Actual Drug Content in microsponges 
Theoretical Drug Content
× 100 
Morphology and Surface topography: Developed tazarotene 
microsponge coated with gold-palladium under an argon 
atmosphere at room temperature and surface morphology studied 
by scanning electron microscopy (SEM). Fractured microsponge 
SEM was also taken to illustrate its ultra-structure [10, 11]. 
Drug content: 100 mg of tazarotene microsponge dissolved in 
methanol and phosphate buffer solution pH 7.4 and allowed to stand 
for 24 h. The solution was filtered through whatman filter paper 
(No.41) and drug content was analyzed spectrophotometrically 
(Shimadzu 1700) at 350 nm, against standard methanolic and 
phosphate buffer solution pH 7.4.  
In vitro dissolution study for the time required to 80% drug release: 
The dissolution profile of tazarotene microsponges studied by use of 
USP Type-I dissolution apparatus with a modified basket consisted 
of 5μm stainless steel mesh. A sample equivalent to 100 mg of 
tazarotene nitrate was taken in the basket. The 100 rpm and 
temperature of 37±0.5˚C w ere maintained throughout the 
experiment. The dissolution medium (900 ml) is phosphate buffer 
pH 7.4 while considering solubility of actives to ensure sink 
conditions. At fixed intervals, aliquots were withdrawn and replaced 
with fresh dissolution medium. Samples from the dissolution 
medium can be analysed by UV spectrophotometer (Shimadzu 
1700) at 350 nm at specific time intervals (1, 2, 3, 4, 5, 6, 7, and 8 
hour). The concentration of drug released at different time intervals 
was determined by measuring absorbance [12, 13]. 
Optimization of tazarotene microsponge by 32 full factorial design 
A 32 full factorial design was employed in the present study. In this 
design 2 factors were evaluated, each at 3 levels and experimental 
trials was performed for all 9 possible combinations. Preliminary 
Screening Two variables, the concentration of Polymer and 
concentration of PVA were found critical. So, they were optimized 
using different trials, while other parameters were kept constant. On 
the basis of preliminary results, concentration of Polymer (X1) and 
concentration of PVA (X2) were chosen as independent variables in 
32 full factorial design, while Particle Size (Y1), % Drug entrapment 
(Y2), Time required to 80% drug release (Y3) was selected as 
dependent variables. Multiple linear regression analysis, ANOVA and 
graphical representation of the influence of factor by 3D plots were 
performed using of sigma plot software 11.0. The experimental runs 
and measured responses of 32 full factorial design batches of 
tazarotene microsponge depleted in table 2 [14, 15]. 
Development of 0.1% tazarotene microsponge topical gel 
The topical gel was developed by dissolving 3% w/w HPMC K100 M 
in a sufficient amount of pH 7.4 citrate phosphate buffer. Gel was 
kept overnight to remove air bubble and add benzyl alcohol (1% 
v/v) as a preservative. Then, add a tazarotene microsponge (0.1 
%w/w) to gel with geometric dilution [16, 17]. 
Evaluation of 0.1 % tazarotene microsponge topical gel 
Viscosity: The viscosity of the gel was determined by Brookfield 
Viscometer (Model-LVDV-E). It was determined using with spindle 
no. 64 at 100 rpm at temperature 25̊ C. Rotate the spindle in the 
microsponge gel till get a constant dial reading.  
pH: The pH of gel was determined by a digital pH meter. One gram of 
gel was dissolved in 100 ml distilled water and stored for 2 hr. Then, 
electrode was the dipped into gel for 30 min until constant reading 
obtained. 
Drug content: 1 gm of microsponge gel was accurately weighed and 
dissolved in pH 7.4 citrate phosphate buffer using sonicator. A 
sample from this aliquot was analyzed by UV spectrophotometer 
(Shimadzu 1700) at 350 nm [18, 19]. 
Spreadability: Spreadability apparatus consists of a wooden block with 
a ground glass plate (20X20) fixed on to it. A pre-determined amount 
of gel was placed on ground glass plate and it was sandwich with 
another glass plate. Accurately 500 gm weight was placed on the top of 
the two glass plate to expel the air and provide a uniform film of the 
gel between the plates. Excess of gel was wiped off. The top plate was 
subjected to a put 10 gm weight and allows slipping the plate. The 
spreadability was calculated by using the following equation. 
S = ML T⁄ . 
Where, S= spreadability M = weight on top plate (10 gms) L= length 
of the glass plate, T=time taken to separate the plat completely from 
each other. 
In-vitro diffusion study: The release from the gels was examined through 
a cellophane membrane using a modified Franz diffusion cell. Prior to 
study, the cellophane membrane was soaked in diffusion medium for 4 
hr and then placed on diffusion cell assembly. An aqueous solution of 
citrate phosphate buffer pH 7.4 was used as the receptor medium and 1 
gm of the test gel was placed on the donor side. The receptor medium 
was kept at 37±0.5 °C. At predetermined time intervals, sample was 
taken from the receptor compartment and replaced with the fresh 
citrate phosphate buffer pH 7.4. Absorbance of the solutions was 
measured spectrophotometrically (Shimadzu 1700) at 350 nm [20, 21]. 
Kinetic Modelling of Dissolution Data: In order to understand the 
kinetics and release mechanisms of drug, the result of in vitro 
diffusion study of gel was fitted in with various kinetics models like 
zero order, first order, Higuchi model and Korsmeyer Peppas model. 
The linearity of the plots was obtained from the value of regression 
co-efficient (R). The model with the highest linearity (R2 value) was 
chosen as the Best-fit kinetic model [22, 23]. 
Photostability study: Prepared 0.1% tazarotene microsponge containing 
gel was filled in clear polypropylene syringes, one for test and other for 
control. It was assayed by UV spectrophotometry immediately after 
preparation and analyzed the drug content. This study was carrying out 
for measurement of initial concentration. Then same tazarotene 
microsponge containing gel (0.1%) were exposed to UV light with an 
integrated intensity from 352 nm of 22 watt/m for 8 h. This spectral 
region was selected to provide a more energetic exposure than visible 
light and is consistent with the International Conference on 
Harmonization (ICH) guidelines for photostability testing [24]. 
RESULTS AND DISCUSSION 
Drug excipients compatibility study 
Fourier transform infrared spectroscopy (FT-IR) was used to study the 
physical and chemical interactions between drug and excipients. FT-IR 
spectra of tazarotene and mixture of tazarotene with eudragit RS-100 
were recorded using KBr mixing method on FT-IR instrument. The 
drug exhibited peaks due to amide group, alcohol group and C-H, C=O, 
C-O, C-N and C=C stretching. It was observed that there were no or 
very minor changes in drug main peaks in the IR spectra of the 
mixture and pure drug. The FTIR study revealed no physical or 
chemical interaction of tazarotene with eudragit RS-100 [25]. 
Preliminary screening of formulation parameters 
Preliminary trial of tazarotene microsponge result was shown in 
table 1. Good % of yield and mean particle size observed in batch T-1 
which containing eudragit RS-100. Stickiness was detecting in batch 
T-2 which containing eudragit RL-100. Particle size found uneven 
when we use ethyl cellulose in batch T-3. HPMC K4M was separate 
out form the solvent in batch T-4. So, further investigation was using 
with eudragit RS-100. Uneven particle size was observed in batch T-
5 and T-7. So, 1000 rpm was selected for further Preliminary trial 
batch. Batch T-8 was given a higher % of yield compare to batch T-9. 
The results of preliminary study revealed that eudragit RS100 and 
PVA both required achieving the desired release profile. Hence, 
further trials were carried out using various combinations eudragit 
RS100 and PVA in order to understand their effect and to optimize 
concentration of both for desired release profile. 
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Fig. 1: IR spectrum of tazarotene Fig. 2: IR spectrum of tazarotene and eudragit RS-100 
 
32 Full factorial design model evaluation 
A statistical model incorporating interactive and polynomial terms 
was used to evaluate the responses:  
Y=b0+b1X1+b2X2+b11X12+b22X22+b12X1X2 
where, Y is the dependent variable, bo is the arithmetic mean 
response of the 9 runs and any bi is the estimated coefficients for the 
related factor Xi. The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high value. The 
polynomial terms (X12 and X22) are included to investigate 
nonlinearity. The interaction term “X1X2” shows how the response 
changes when the two factors change simultaneously. Evaluation 
data for tazarotene microsponge were presented in table 2. The 
fitted equations relating the responses that is, particle size (Y1), % 
drug entrapment (Y2), the time required to 80% drug release (T80) 
(Y3) was to the transformed factor are shown in table 3. The 
polynomial equations can be used to draw conclusions after 
considering the magnitude of coefficient and the mathematical sign 
it carries (i.e. positive or negative). The results of ANOVA suggested 
that calculated F values for particle size, % drug entrapment, time 
required to 80% drug release (T80) are 99.077, 9.666 and 14.673 
respectively (table 4). Tabulated F value was found to be 9.013 at α 
= 0.05. Calculated F values are greater than tabulated for all 
dependent variables, therefore, factors selected have shown 
significant effects. From the results of multiple regression analysis, it 
was found that all factors had statistically significant influence on all 
dependent variables as p<0.05 [26, 27]. 
 
Table 1: Evaluation of preliminary screening batch of tazarotene microsponge 








Time required to 80% 
drug release  
T-1 0.1 % Eudragit RS100 1000 0.5 68.50±1.75 67.64±1.12 178±4 360±4 
T-2 0.1 % Eudragit RL100 1000 0.5 71.75±2.45 63.45±2.78 456±5 350±3 
T-3 0.1 % Ethyl cellulose 1000 0.5 62.50±0.89 55.90±0.36 576±1 310±5 
T-4 0.1 % HPMC K4M 1000 0.5 - - - - 
T-5 0.1 % Eudragit RS100 500 0.5 71.25±2.56 66.95±0.78 778±6 340±5 
T-6 0.1 % Eudragit RS100 1000 0.5 76.00±1.13 72.29±0.34 207±3 390±5 
T-7 0.1 % Eudragit RS100 1500 0.5 80.90±1.67 72.04±1.78 158±6 440±3 
T-8 0.1 % Eudragit RS100 1000 0.5 74.00±0.56 67.25±0.67 156±4 400±2 
T-9 0.1 % Eudragit RS100 1000 1.0 43.15±2.23 42.05±1.25 716±6 320±4 
n=6 
 
Table 2: Runs and measured responses of 32factorial design for tazarotene microsponge 
Batch 
code 
% of Eudragit RS-
100(X1) 




% Drug entrapment  
(Y2) 
Time required to 80% drug 
release (Y3) 
F1 -1 -1 158±2 73.20±2.34 390±4 
F2 -1 0 180±5 74.95±0.82 415±1 
F3 -1 1 196±2 66.70±1.11 430±5 
F4 0 -1 193±5 77.80±2.31 380±1 
F5 0 0 204±4 89.19±1.09 415±3 
F6 0 1 227±2 75.46±0.86 420±6 
F7 1 -1 213±4 72.09±1.34 435±2 
F8 1 0 226±3 84.67±2.51 440±5 
F9 1 1 238±2 78.93±0.88 445±3 
Factors and the levels in the design 
Independent variables Low (-1) Medium (0) High (1) 
% of Eudragit RS100(X1) 0.05  0.1 0.15 
% of PVA (X2)  0.25  0.50  0.75 
 
Full and reduced model for particle size  
Particle size = 207.444+(23.833 * X1)+(16.167 * X2)-(6.167 * 
X12)+(0.833 * X12)-(3.250 * X1 X2) 
From the 3D plot (fig. 3) and the regression coefficient values of 
factors, it was concluded that when % of eudragit RS-100and % of 
PVA was increased that time particle size also increase and it’s lead 
to more drug entrapment. The results also indicated that the 
eudragit RS-100was given a more significant on particle size. Both 
the eudragit RS-100and % of PVA showed significant effect in the 
model. Interaction and nonlinearity were not observed. For particle 
size, the significance levels of the coefficients b12, b22 and b12 were 
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found to be P= 0.073, 0.738 and 0.136respectively, so they were 
omitted from the full model to generate a reduced model. The 
coefficients b1 and b2 were found to be significant at P<0.05; hence, 
it was retained in the reduced model. SEM of tazarotene 
microsponge was shown in fig. 6. The reduced model for Particle 
Size, 
=207.444+(23.833 * X1)+(16.167 * X2)
 
 
Fig. 3: 3D plot showing the effect of % of eudragit RS-100(X1) and 
PVA (X2) on particle size (Y1) 
 
Fig. 4: 3D plot showing the effect of eudragit RS-100(X1) and PVA 
(X2) on % of drug entrapment (Y2) 
 
Fig. 5: 3D plot showing the effect of eudragit RS-100(X1) and PVA 
(X2) on time required to 80% drug release 
 
Fig. 6: SEM of tazarotene microsponge 
 
Full and reduced model for % of drug entrapment 
% of drug entrapment = 86.754+(3.473 X1)-(0.333 X2)-(5.727 X12)-
(8.907 X22)+(3.335 X1 X2)  
From the 3D plot (fig. 4) and the regression coefficient values of 
factors, it was concluded that corresponding increase in the % drug 
entrapment of microsponge was observed with increase in con. of 
eudragit RS-100. From regression, it is observed that X1 was 
significant model terms which affect the % of drug entrapment. 
Interaction and non-linearity was not observed. For % of drug 
entrapment, the significance levels of the co-efficients b2, b11 and b12 
were found to be P= 0.779, 0.056 and 0.087, respectively. So, they 
were omitted from the full model to generate a reduced model. The 
co-efficients b1 and b22 were found to be significant at P<0.05; hence 
they were retained in the reduced model. The reduced model for % 
drug entrapment, 
= 86.754+(3.473 X1)-(8.907 X22)
 
Table 3: Summary of regression output of factors for measured responses 
Responses Model Coefficient of regression parameters 
b0 b1 b2 b11 b22 b12 R2 
Particle Size Full 207.444 23.833 16.167 6.167* 0.833* 3.250* 0.994 
Reduced 207.444 23.833 16.167 - - - 
% Drug entrapment Full 86.754 3.473 0.333* 5.727* 8.907 3.335* 0.942 
Reduced 86.754 3.473 - - 8.907 - 
Time required to 80% drug release Full 409.444 14.167 15.000 20.833 6.667* 7.500* 0.961 
Reduced 409.444 14.167 15.000 20.833 - - 
*indicated the coefficient with p>0.05 
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Table 4: Results of the ANOVA for dependent variables 
Particle size 
Source of variation DF SS MS F P 
Regression 5 5096.028 1019.206 99.077 0.002 
Residual 3 30.861 10.287 
Total 8 5126.889 640.861 
% Drug entrapment 
Source of variation DF SS MS F P 
Regression 5 341.787 68.357 9.666 0.045 
Residual 3 21.215 7.072 
Total 8 363.002 45.375 
Time required to 80% drug release 
Source of variation DF SS MS F P 
Regression 5 3736.111 747.222 14.673 0.026 
Residual 3 152.778 50.926 
Total 8 3888.889 486.111 
 
Full and reduced model for time required to 80% drug release 
Time required to 80% drug release = 409.444+(14.167 X1)+(15.000 
X2)+(20.833 X12)-(6.667 X22)-(7.500 * X1 X2) 
From the 3D plot (fig. 5) and the regression coefficient values of 
factors, it was concluded that corresponding increase in the time 
required to 80% drug release of microsponge was observed with 
increase in concentration of polymer and PVA concentration. From 
regression it is observed that X1 and X2 were equivalent significant 
model terms which affect the on drug release. Interaction and 
nonlinearity were not observed. For time required to 80% drug 
release, the significance levels of the coefficients b22 and b12 were 
found to be P= 0.278 and 0.126 respectively. So, it was omitted from 
the full model to generate a reduced model. The coefficients b1, b2 
and b11 were found to be significant at P<0.05; hence they were 
retained in the reduced model. The reduced model for time required 
to 80% drug release [28, 29] 
= 409.444+(14.167 X1)+(15.000 X2)+(20.833 X12)  
Formulation of checkpoint batch 
To validate the evolved mathematical models, a checkpoint batches 
CP1 was prepared and evaluated. The observed and predicted values 
for batch CP1 were shown in table 5. Good correlation was found 
between observed and predicted values shown in table 6. Hence, it 
was concluded that the evolved models may be used for theoretical 
prediction of responses within the factor space. 
 
Table 5: Formulation of checkpoint batches 
Batch code Variable level 
Coded value Actual value 
X1 X2 X1(mg) X2(ml) 
CP1 -0.5 -0.5 0.075 0.375 
 
Table 6: Evaluation of checkpoint batches and comparison with the predicted value 
Parameter Actual value Predicted value 
Particle Size (µm) (Y1) 78±2 80.812 
% Drug entrapment (Y2) 84.24±1.22 87.244 
Time required to 80% drug release (Y3) 403±4 409.943 
(n=6) 
 
Selection of optimized batch in the factorial design study 
In the present study, the following constraints were arbitrarily used 
for the selection of an optimized batch: particle size<200 µm, drug 
entrapment>70 %, and time required to 80% drug release>360 min. 
Batches F1, F2, F3, and F4 met the selection criteria. Batch F1 showed 
lowest particle size (158 µm) and 80 % drug release in 390 min. 
Hence, Batch F1 was selected as an optimized batch. The optimized 
formulation was added into the 3% HPMC K-100M gel. [29, 30] 
Evaluation of 0.1% tazarotene microsponge topical gels 
The optimized tazarotene microsponge formulation batch F-1 was 
subjected to further characterization studies and incorporated into 
gel to get homogenous based delivery systems. The gel was 
prepared by using 3% HPMC K-100M. The prepared gel was 
evaluated for physicochemical characteristics and it showed desired 
drug content, in vitro diffusion, spreadability, pH and viscosity as per 
standard criteria as shown in table 7. The gel color was white and 
that color was stable along the period of evaluation. The drug 
content was found 87.27±2.32%. It showed a good content 
uniformity for the prepared microsponge. The viscosity of the gel 
was found 2933.33±12 cp. The pH of tazarotene microsponge gel 
was found 7.06±0.21 and it was indicated topical gel was safe, stable 
and non-irritate. The values of spreadability indicated that the gel 
was easily spreadable by a small amount of shear. Spreadability of 
tazarotenemicrosponge gel was found to be 16.98±0.51 gm. cm/sec 
indicating that spreadability of drug-loaded microsponge gel was 
good. The in-vitro diffusion studies were carried out for 
tazarotenemicrosponge gel using citrate phosphate buffer pH 7.4.  
In vitro diffusion of formulation is shown in fig. 7. It was observed 
that the gel formulation showed a drug diffused upto 10 hr. The 
results indicated that the cumulative amount of drug permeated per 
unit skin surface area from the microsponge loaded gel formulation 
was 93.40% for 10 hr. To determine the kinetics of release, drug 
diffusion data were treated with different kinetic equations. 
Obtained drug diffusion data was fitted to Zero order, First order, 
Higuchi model and Korsmeyer-peppas model. The correlation 
coefficient (R) was used to study the release mechanism of 
tazarotenemicrosponge gel is reported in table 7. The model that 
gave the high ‘R’ value was considered as the best fit of release data. 
From the result, the best fit model for tazarotenemicrosponge gel 
formulation is Zero order (R2= 0.987). 0.1% Tazarotene 
Microsponge Topical Gel was kept for photostability study to UV 
light with an integrated intensity from 352 nm of 22 watt/m for 8 h. 
Initial drug content was found 87.27±2.32 % and after 8 hdrug 
content was 80.63±1.42 %. There is no significant difference in drug 
content after photo stability study result shown in table 8. 
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Table 7: Evaluation of 0.1% tazarotene microsponge topical gel 
Parameter Topical gel 
Viscosity  2933.33±12.56 cp 
pH 7.06±0.21 
Spreadability 16.98±0.51 gm. cm/sec 
Drug content 87.27±2.32 % 
Zero order R2 0.987 
First order R2 0.939 
Higuchi model R2 0.985 




Fig. 7: In vitro diffusion study tazarotene microsponge topical gel 
 
Table 8: Photostability study of 0.1% tazarotene microsponge topical gel 
Description Initial drug content Drug content after 8 h 
Test sample 87.27±2.32 % 80.63±1.42 % 
Control sample 87.27±2.32 % 87.26±0.89 % 
 
CONCLUSION 
The present study concluded successful preparation and optimization 
of 0.1 % tazarotene loaded microsponge gel with the enhanced the 
availability of drug at the site of action. In vitro andKinetic Modelling of 
Dissolution Data evaluation of microsponge gel revealed remarkable 
and enhanced topical retention of drug for prolonged period of time. A 
controlled release of tazarotene onto the skin over a prolonged period 
of time was beneficial for psoriasis treatment. This study provides 
future insights for developing controlled release microsponge gels for 
topical applications containing retinoid. 
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